Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design

Viegas, EO; Kroidl, A; Munseri, PJ; Missanga, M; Nilsson, C; Tembe, N; Bauer, A; ... Lyamuya, E; + view all Viegas, EO; Kroidl, A; Munseri, PJ; Missanga, M; Nilsson, C; Tembe, N; Bauer, A; Joachim, A; Joseph, S; Mann, P; Geldmacher, C; Fleck, S; Stöhr, W; Scarlatti, G; Aboud, S; Bakari, M; Maboko, L; Hoelscher, M; Wahren, B; Robb, ML; Weber, J; McCormack, S; Biberfeld, G; Jani, IV; Sandström, E; Lyamuya, E; - view fewer (2018) Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design. PLoS One , 13 (11) , Article e0206838. 10.1371/journal.pone.0206838 . Green open access

https://ift.tt/2UeqK1f